The stock of Gilead Sciences, Inc. (GILD) has gone down by -2.17% for the week, with a -10.36% drop in the past month and a -20.28% drop in the past quarter. The volatility ratio for the week is 1.39%, and the volatility levels for the past 30 days are 1.41% for GILD. The simple moving average for the last 20 days is -5.24% for GILD stock, with a simple moving average of -11.46% for the last 200 days.
Is It Worth Investing in Gilead Sciences, Inc. (NASDAQ: GILD) Right Now?
The price-to-earnings ratio for Gilead Sciences, Inc. (NASDAQ: GILD) is 15.11x, which is above its average ratio. Moreover, the 36-month beta value for GILD is 0.21. Analysts have varying opinions on the stock, with 11 analysts rating it as a “buy,” 2 as “overweight,” 15 as “hold,” and 0 as “sell.”
The public float for GILD is 1.25B and currently, short sellers hold a 1.81% of that float. On April 15, 2024, GILD’s average trading volume was 7.41M shares.
GILD) stock’s latest price update
The stock price of Gilead Sciences, Inc. (NASDAQ: GILD) has plunged by -0.84 when compared to previous closing price of 68.65, but the company has seen a -2.17% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-09 that In the most recent trading session, Gilead Sciences (GILD) closed at $69.94, indicating a +0.75% shift from the previous trading day.
Analysts’ Opinion of GILD
Many brokerage firms have already submitted their reports for GILD stocks, with Truist repeating the rating for GILD by listing it as a “Hold.” The predicted price for GILD in the upcoming period, according to Truist is $82 based on the research report published on February 22, 2024 of the current year 2024.
Deutsche Bank, on the other hand, stated in their research note that they expect to see GILD reach a price target of $75. The rating they have provided for GILD stocks is “Hold” according to the report published on November 09th, 2023.
BofA Securities gave a rating of “Buy” to GILD, setting the target price at $95 in the report published on September 08th of the previous year.
GILD Trading at -7.01% from the 50-Day Moving Average
After a stumble in the market that brought GILD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.53% of loss for the given period.
Volatility was left at 1.41%, however, over the last 30 days, the volatility rate increased by 1.39%, as shares sank -8.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.02% lower at present.
During the last 5 trading sessions, GILD fell by -2.17%, which changed the moving average for the period of 200-days by -10.45% in comparison to the 20-day moving average, which settled at $71.52. In addition, Gilead Sciences, Inc. saw -15.97% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GILD starting from GILEAD SCIENCES, INC., who purchase 485,250 shares at the price of $0.76 back on Apr 02 ’24. After this action, GILEAD SCIENCES, INC. now owns 7,345,473 shares of Gilead Sciences, Inc., valued at $368,790 using the latest closing price.
Parsey Merdad, the Chief Medical Officer of Gilead Sciences, Inc., sale 2,000 shares at $72.96 during a trade that took place back on Apr 01 ’24, which means that Parsey Merdad is holding 96,304 shares at $145,920 based on the most recent closing price.
Stock Fundamentals for GILD
Current profitability levels for the company are sitting at:
- 0.31 for the present operating margin
- 0.78 for the gross margin
The net margin for Gilead Sciences, Inc. stands at 0.21. The total capital return value is set at 0.17. Equity return is now at value 25.71, with 9.04 for asset returns.
Based on Gilead Sciences, Inc. (GILD), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at 0.32. The debt to equity ratio resting at 1.1. The interest coverage ratio of the stock is 9.0.
Currently, EBITDA for the company is 11.7 billion with net debt to EBITDA at 1.92. When we switch over and look at the enterprise to sales, we see a ratio of 3.83. The receivables turnover for the company is 5.82for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.
Conclusion
To wrap up, the performance of Gilead Sciences, Inc. (GILD) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
